<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792021</url>
  </required_header>
  <id_info>
    <org_study_id>N-acetylcysteine in COVID 19</org_study_id>
    <nct_id>NCT04792021</nct_id>
  </id_info>
  <brief_title>Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients</brief_title>
  <official_title>Effect of N-acetylcysteine on Oxidative Stress And Occurrence of Complications in Patients With COVID 19 Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the potential therapeutic effect of N-acetylcysteine&#xD;
      &quot;NAC&quot; in COVID 19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 (&#xD;
      COVID-19) infection who are classified as moderate cases and require hospitalization.&#xD;
      Patients meeting eligibility criteria will be randomized either to receive oral&#xD;
      N-acetylcysteine or not along with the institution treatment protocol . Treatment efficacy&#xD;
      will be assessed using certain endpoints as follows:&#xD;
&#xD;
        1. Markers of inflammation and oxidative stress&#xD;
&#xD;
        2. Length of hospital stay&#xD;
&#xD;
        3. Need for ventilation&#xD;
&#xD;
        4. Mortality rate&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two groups in parallel for the duration of the study.&#xD;
One arm is the intervention arm: those receiving N-acetylcysteine (NAC). One arm is the control group : those not receiving N-acetylcysteine (NAC).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TNF alfa level from baseline</measure>
    <time_frame>from enrollment till the end of treatment at 2 weeks or until hospital discharge or death</time_frame>
    <description>The mean change in TNF alfa is used to assess NAC efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6 level from baseline</measure>
    <time_frame>from enrollment till the end of treatment at 2 weeks or until hospital discharge or death</time_frame>
    <description>The mean change in IL-6 level is used to assess NAC efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glutathione peroxidase level from baseline</measure>
    <time_frame>from enrollment till the end of treatment at 2 weeks or until hospital discharge or death</time_frame>
    <description>The mean change in glutathione peroxidase is used to assess NAC efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Through study completion ( average 9 months)</time_frame>
    <description>Duration of hospital stay for admitted patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for mechanical ventilation</measure>
    <time_frame>Through study completion ( average 9 months)</time_frame>
    <description>Whether a patient required mechanical ventilation (intubation) or not</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Corona Virus Disease 19 (Covid19)</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine (NAC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving N-acetylcysteine (NAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients not receiving N-acetylcysteine (NAC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>Oral formulation: 600 mg sachets of N-acetylcysteine</description>
    <arm_group_label>N-acetylcysteine (NAC)</arm_group_label>
    <other_name>Acetylcysteine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged more than 18 years&#xD;
&#xD;
          2. Documented COVID-19 infection (either performed on site or documented external&#xD;
             report), only moderate cases will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or hypersensitivity to NAC&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Critically ill or mechanically ventilated patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara M. Sherkawy, B.S.P</last_name>
    <role>Principal Investigator</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lamia El Wakeel, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Schaalan, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman Moharram, Professor</last_name>
    <role>Study Director</role>
    <affiliation>El Kasr El Einy Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara M Sherkawy, B.S.P</last_name>
    <phone>+201061350305</phone>
    <email>sara.mohamed@miuegypt.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Al Assema Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman Moharram, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sara Mohamed Sherkawy</investigator_full_name>
    <investigator_title>Principal Investigator at the Faculty of pharmacy</investigator_title>
  </responsible_party>
  <keyword>N-acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

